What is the clinical evidence from this study?

Study design: Cohort. Population: Cardiac surgery-associated acute kidney injury (CSA-AKI) (n=3431). Intervention: Perioperative dexmedetomidine vs. No dexmedetomidine use. Primary outcome: Renal non-recovery following acute kidney injury (OR 0.77, 95% CI 0.62-0.96, p=0.021).

What question did this study set out to answer?

To investigate the association between perioperative dexmedetomidine administration and renal function recovery in patients with cardiac surgery–associated acute kidney injury.

September 8, 2026Perioperative MedicineOpen Access

Perioperative dexmedetomidine use and renal recovery in cardiac surgery–associated acute kidney injury: a MIMIC-IV database study

Q: What are the key findings of this study?

Perioperative dexmedetomidine use was associated with a significantly lower risk of renal non-recovery compared with non-use (OR 0.77) in patients with cardiac surgery-associated acute kidney injury.

Q: What does this research mean for the field?

Perioperative dexmedetomidine use is associated with a significantly lower risk of renal non-recovery in patients with cardiac surgery-associated acute kidney injury, particularly among high-risk subgroups. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Perioperative dexmedetomidine is linked to ~23% lower risk of renal non-recovery in cardiac surgery-associated AKI.

OR 0.77
95% CI 0.62-0.96
P=0.021
n=3,431

Why the study?

Does perioperative dexmedetomidine improve renal function recovery in adult patients with cardiac surgery-associated acute kidney injury?

Population

3,431 adult patients who developed acute kidney injury (AKI) following cardiac surgery

Comparison

Perioperative dexmedetomidine administration vs No perioperative dexmedetomidine administration

Design

Cohort

Authors

QCQiu ChenWuhan University DJDongli JieWuhan University YDYanfei DongHuazhong University of Science and Technology

Discussion

Member takes

Implication

May inform dexmedetomidine use in cardiac surgery; leaves open its impact on renal recovery after CSA-AKI pending randomized evidence.

Key Points

To investigate the association between perioperative dexmedetomidine administration and renal function recovery in patients with cardiac surgery–associated acute kidney injury.
Analyzed data from 3,431 adult patients with cardiac surgery–associated acute kidney injury in the MIMIC-IV database (2008–2022), comparing 1,019 patients who received perioperative dexmedetomidine with 2,412 who did not.
Used propensity score matching to balance baseline covariates and multivariable logistic regression to evaluate renal recovery, supplemented by subgroup analyses based on acute kidney injury stage, cardiac surgery type, drug dose, and infusion duration.
Renal recovery occurred in 77.85% of patients (2,671/3,431) overall, and dexmedetomidine use was significantly associated with a decreased risk of renal non-recovery (OR = 0.77, 95% CI: 0.62–0.96, P = 0.021).
Improved recovery was significantly associated with dexmedetomidine in patients with more severe acute kidney injury, those undergoing valvular surgery, higher doses (≥ 3.97 μg/kg/h), and shorter durations (< 12 h) (all P < 0.05).

Study Design

Type

Cohort (n=3,431)

Multicenter

Structured PICO

Does perioperative dexmedetomidine improve renal function recovery in adult patients with cardiac surgery-associated acute kidney injury?

Population

3,431 adult patients with cardiac surgery-associated acute kidney injury, followed until hospital discharge, to evaluate the association of perioperative dexmedetomidine use with renal function recovery.

Exposure

Perioperative dexmedetomidine administration

Comparator

No perioperative dexmedetomidine administration

Outcome

Renal function recoveryhard clinical

Main Result

Odds Ratio: 0.77 (95% CI 0.62–0.96)

Absolute Event Rate: 18.25% vs 22.37%

p-value: p=0.021

Perioperative dexmedetomidine use is associated with improved renal function recovery in patients with cardiac surgery-associated acute kidney injury, particularly in high-risk subgroups.

Limitations

Retrospective observational design precludes causal inference and residual confounding cannot be entirely excluded
Lack of detailed perioperative information such as surgical urgency, specific clinical indications, and dose titration protocols
Inability to reliably differentiate between isolated and combined cardiac surgical procedures
Exclusion of patients with ICU stays shorter than 48 hours may limit applicability to patients with shorter postoperative ICU courses
Single-center study population may represent a less severely ill cohort, limiting generalizability

Cite This Study

Chen et al. (2026) conducted a cohort in Cardiac surgery-associated acute kidney injury (CSA-AKI) (n=3,431). Perioperative dexmedetomidine vs. No dexmedetomidine use was evaluated on Renal non-recovery following acute kidney injury (OR 0.77, 95% CI 0.62-0.96, p=0.021). Perioperative dexmedetomidine use was associated with a significantly lower risk of renal non-recovery compared with non-use (OR 0.77) in patients with cardiac surgery-associated acute kidney injury.

synapsesocial.com/papers/6aa0091858e84d0ff5b47cb6 https://doi.org/10.1186/s13741-026-00740-y

View Full Paper

Ask AI

Bookmark

Perioperative dexmedetomidine use and renal recovery in cardiac surgery–associated acute kidney injury: a MIMIC-IV database study

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Perioperative dexmedetomidine use and renal recovery in cardiac surgery–associated acute kidney injury: a MIMIC-IV database study

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider